BRCA2 and neoplasm: A homologous recombination deficiency typically associates with “BRCAness” of breast tumors due to mutational inactivation of the BRCA1 and BRCA2 tumor suppressor genes, making these tumors susceptible to poly-ADP ribose polymerase (PARP) inhibitors.